Clofoctol
 | |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Rectal (suppository)[1] |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | 98%[1] |
| Metabolism | Hepatic glucuronidation[1] |
| Excretion | Biliary[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.048.739 |
| Chemical and physical data | |
| Formula | C21H26Cl2O |
| Molar mass | 365.34 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Clofoctol is a bacteriostatic antibiotic. It is used in the treatment of respiratory tract and ear, nose and throat infections caused by Gram-positive bacteria.[1] It has been marketed in France till 2005 under the trade name Octofene and in Italy as Gramplus.[citation needed]
It is only functional against Gram-positive bacteria.[2]
It penetrates into human lung tissue.[3]
A French company, Apteeus had been developing clofoctol as a potential therapy against SARS-CoV-2 in 2020-2021, but eventually the repurposing of the drug was abandoned, due to a lack of volunteers.[4][5][6][7][8][9] A mouse study showed repurposed drug clofoctol blocks SARS-CoV-2 replication.[10][11]
References
[edit]- ^ a b c d e "Gramplus" (in Italian). Studio Medico Torrino. July 25, 2007. Archived from the original on March 8, 2016. Retrieved 2007-08-10.
- ^ Combe J, Simonnet F, Yablonsky F, Simonnet G (1980). "[Clofoctol binding by the bacteria (author's transl)]". Journal de Pharmacologie (in French). 11 (4): 411–425. PMID 6782374.
- ^ Danesi R, Gasperini M, Senesi S, Freer G, Angeletti CA, Del Tacca M (1988). "A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay". Drugs Under Experimental and Clinical Research. 14 (1): 39–43. PMID 3391105.
- ^ Marcelli S (2020-10-13). "Pasteur Lille obtient 5 M€ de LVMH pour repositionner un ancien médicament, l'Octofene, sur le traitement du Covid" [Pasteur Lille obtains €5 million from LVMH to reposition an old drug, Octofene, for the treatment of Covid] (in French). AEF info. Archived from the original on 2020-10-17. Retrieved 2020-10-13.
- ^ Haroche F (2021-09-13). "La piste clofoctol. Interview du Pr Xavier Nassif". Jim.fr. Archived from the original on 2021-09-13.
- ^ "Hope for an Anti-COVID Drug". arte.tv. ARTE Reportage. ARTE G.E.I.E. 2021-05-21. Archived from the original on 2022-05-27. Retrieved 2024-06-03.
- ^ Blanquart J, Tonolli F (2022-07-04). "La molécule miracle !" [The miracle molecule!]. Wéo (in French). Archived from the original on 2022-07-16. Retrieved 2024-06-03.
- ^ Mounier JL (2020-10-01). "French institute aims to start human trials of 'promising' Covid-19 drug this winter". France 24. Archived from the original on 2020-10-01. Retrieved 2024-06-02.
- ^ Demollien N (2020-06-20). "Covid-19 : un reportage sur les chercheurs de l'institut Pasteur de Lille ce samedi sur Arte" [Covid-19: a report on researchers from the Pasteur Institute in Lille this Saturday on Arte]. actu.fr (in French). Archived from the original on 2020-06-21. Retrieved 2024-06-02.
- ^ Thomas L (2022-05-23). "Repurposed drug clofoctol blocks SARS-CoV-2 replication in mouse study". News-Medical. Archived from the original on 2022-05-23. Retrieved 2024-06-02.
- ^ Belouzard S, Machelart A, Sencio V, Vausselin T, Hoffmann E, Deboosere N, et al. (May 2022). Menachery VD (ed.). "Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice". PLOS Pathogens. 18 (5): e1010498. doi:10.1371/journal.ppat.1010498. PMC 9119441. PMID 35587469.
 | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |